These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 23565755)

  • 1. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
    Fiandalo MV; Wu W; Mohler JL
    Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment.
    Fiandalo MV; Wilton J; Mohler JL
    Int J Biol Sci; 2014; 10(6):596-601. PubMed ID: 24948872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.
    Wadosky KM; Koochekpour S
    Oncotarget; 2016 Sep; 7(39):64447-64470. PubMed ID: 27487144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
    Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
    Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
    Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
    Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.
    Verone AR; Duncan K; Godoy A; Yadav N; Bakin A; Koochekpour S; Jin JP; Heemers HV
    Carcinogenesis; 2013 Aug; 34(8):1737-46. PubMed ID: 23576568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor: past, present and future.
    Schmidt LJ; Tindall DJ
    Curr Drug Targets; 2013 Apr; 14(4):401-7. PubMed ID: 23565753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
    Kahn B; Collazo J; Kyprianou N
    Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.
    Mooso BA; Vinall RL; Tepper CG; Savoy RM; Cheung JP; Singh S; Siddiqui S; Wang Y; Bedolla RG; Martinez A; Mudryj M; Kung HJ; Devere White RW; Ghosh PM
    Endocr Relat Cancer; 2012 Dec; 19(6):759-77. PubMed ID: 22993077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
    Sabnis NG; Miller A; Titus MA; Huss WJ
    Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation.
    Nelson EC; Cambio AJ; Yang JC; Lara PN; Evans CP
    Nat Clin Pract Urol; 2007 Feb; 4(2):82-94. PubMed ID: 17287869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.
    Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT
    Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
    Karantanos T; Corn PG; Thompson TC
    Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-arm androgen blockade for advanced prostate cancer: a review.
    Desai MH; Parsi M; Potdar RR
    Med Oncol; 2021 May; 38(7):75. PubMed ID: 34032938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of androgen receptor targeted therapy for advanced prostate cancer.
    Wong YN; Ferraldeschi R; Attard G; de Bono J
    Nat Rev Clin Oncol; 2014 Jun; 11(6):365-76. PubMed ID: 24840076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.